08.08 Valeant ïëàíèðóåò êðóïíîå ñëèÿíèå

Îäèí èç êðóïíåéøèõ êàíàäñêèõ ôàðìïðîèçâîäèòåëåé, ÷üè àêöèè íàõîäÿòñÿ â ñâîáîäíîì îáðàùåíèè Valeant Pharmaceuticals, ïðîäîëæàåò îáñóæäàòü âîçìîæíîñòü ïîòåíöèàëüíîãî êðóïíîãî ñëèÿíèÿ. Ïðè ýòîì êîìïàíèÿ íå íàìåðåíà äî êîíöà 2013 ã. ñíèæàòü àêòèâíîñòü â îòíîøåíèè ìåíåå ãëîáàëüíûõ ñäåëîê.

Ïîìèìî íåäàâíåãî ïðèîáðåòåíèÿ êîìïàíèè Bausch&Lomb çà 8,7 ìëðä äîëë, êàíàäñêèé ôàðìïðîèçâîäèòåëü ïëàíèðóåò äî êîíöà 2013 ãîäà åù¸ íåñêîëüêî íåáîëüøèõ ïðèîáðåòåíèé, êîòîðûå âîéäóò â ñòðóêòóðó ñóùåñòâóþùèõ ïîäðàçäåëåíèé, ñîîáùàåò Reuters.

Êðîìå òîãî, èñïîëíèòåëüíûé äèðåêòîð êîìïàíèè Ìàéêë Ïèðñîí çàÿâèë, ÷òî «ñëèÿíèå ðàâíûõ» âñ¸ åù¸ îáñóæäàåòñÿ.